Contribution to Book
Siracusano v. Matrixx Initiatives, Inc.
Top 20 Food And Drug Cases, 2010 & Cases to Watch, 2011
(2011)
Abstract
This chapter discusses the U.S. Court of Appeals' decision in Siracusano v. Matrixx Initiatives, Inc., and its rejection of the "statistical significance" test for the reportability of adverse event report data to securities investors.
Disciplines
Publication Date
2011
Editor
John B. Reiss
Publisher
Food and Drug Law Institute
ISBN
978-1-935065-39-5/02.75
Citation Information
William M Janssen. "Siracusano v. Matrixx Initiatives, Inc." Washington, D.C.Top 20 Food And Drug Cases, 2010 & Cases to Watch, 2011 (2011) Available at: http://works.bepress.com/william_janssen/18/